Bio-Thera IPO Raises $241m
Four-Fifths Of New Funds Earmarked For Development
Bio-Thera, which has just started selling China’s first adalimumab biosimilar rival to AbbVie’s top-selling arthritis treatment Humira, has raised $241m in an IPO on the Shanghai Stock Exchange.
